基于2-乙烯基甲,向素的蛋白激酶和非激酶的不可逆共价抑制剂
Peng Chen1, Guanghui Tang2, Chengjun Zhu3
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
Journal of the American Chemical Society
|February 12, 2023
概括
这项研究引入了一种基于2-乙烯基 (EBA) 的新策略,用于制造选择性,细胞活性素向的不可逆转共价抑制剂. 该方法成功生成了ABL激酶,EGFR和Mcl-1的强效抑制剂,证明了其广泛适用性.
科学领域:
- 医学化学
- 化学生物学
- 药物发现
背景情况:
- 素向性的不可逆转共价抑制剂正在引起人们的兴趣,特别是在酶研究中.
- 对于选择性,细胞活性素向抑制剂的现有化学成分是有限的.
- 向保存的催化素提供了一条通往强效和选择性抑制的途径.
研究的目的:
- 开发一种基于2-乙烯基 (EBA) 的新型策略,用于素向的不可逆转共价抑制剂.
- 产生针对ABL激酶的强效和选择性小分子抑制剂.
- 与EGFR和Mcl-1等其他目标相比,验证EBA战略的普遍性.
主要方法:
- 基于2-乙烯甲 (EBA) 的小分子的设计和合成.
- 对抑制剂的强度,选择性和细胞活性进行评估.
- 评估细胞中对蛋白 (ABL,EGFR,Mcl-1) 的共价作用.
- 分析非目标效应和停留时间.
主要成果:
- 基于EBA的抑制剂通过向其催化溶来强烈和选择性抑制ABL激酶.
- 化合物具有细胞活性,在K562细胞中共聚激活内源ABL激酶,其停留时间长.
- 该策略被通用化为制造EGFR (激酶) 和Mcl-1 (非激酶) 的抑制剂,针对催化和非催化素.
- 观察到最小的目标外接触.
结论:
- 基于2-乙烯基化物 (EBA) 的策略为开发选择性,素向性的不可逆转共价抑制剂提供了多功能平台.
- 这种方法可以制造出针对各种生物向的强效和细胞活性抑制剂,包括激酶和非激酶.
- 开发的抑制剂具有较长的停留时间和标选择性等有利性质,为新的治疗策略铺平了道路.
相关概念视频
Enzyme Inhibition
78.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.9K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.6K
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Targets for Drug Action: Overview
6.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.8K


